US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose–Positron Emission Tomography Imaging: Southwest Oncology Group S0816

作者：Oliver W. Press, Hongli Li, Heiko M. Schöder, David J. Straus, Craig H. Moskowitz, Michael Leo LeBlanc, Lisa M. Rimsza, Nancy L. Bartlett, Andrew M. Evens, Erik Mittra, Ann Steward LaCasce, John William Sweetenham, Paul M. Barr, Michelle A. Fanale, Michael Vinzenz Knopp, Ariela Noy, Eric D. Hsi, James R. Cook, Mary Jo Lechowicz, Randy D. Gascoyne, John Paul Leonard, Brad S. Kahl, Bruce D. Cheson, Richard I. Fisher, Jonathan W. Friedberg · 发表于：Journal of Clinical Oncology · 年份：2016 · DOI：10.1200/jco.2015.63.1119 · 被引用次数：268 · 研究领域：Lymphoma Diagnosis and Treatment、Viral-associated cancers and disorders、CNS Lymphoma Diagnosis and Treatment

PURPOSE: Four US National Clinical Trials Network components (Southwest Oncology Group, Cancer and Leukemia Group B/Alliance, Eastern Cooperative Oncology Group, and the AIDS Malignancy Consortium) conducted a phase II Intergroup clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determine the utility of response-adapted therapy for stage III to IV classic Hodgkin lymphoma. PATIENTS AND METHODS: The Southwest Oncology Group S0816 (Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma) trial enrolled 358 HIV-negative patients between July 1, 2009, and December 2, 2012. A PET scan was performed after two initial cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and was labeled PET2. PET2-negative patients (Deauville score 1 to 3) received an additional four cycles of ABVD, whereas PET2-positive patients (Deauville score 4 to 5) were switched to escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP) for six cycles. Among 336 eligible and evaluable patients, the median age was 32 years (range, 18 to 60 years), with 52% stage III, 48% stage IV, 49% International Prognostic Score 0 to 2, and 51% score 3 to 7. RESULTS: Three hundred thirty-six of the enrolled patients were evaluable. Central review of the interim PET2 scan ...